• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

Here's what to­day's Fed rate cut means for biotech, phar­ma and ven­ture cap­i­tal

7 months ago
Pharma

FDA can­cels Ap­plied Ther­a­peu­tics ad­comm, shares sky­rock­et 65%

7 months ago
FDA+

Keytru­da adds new FDA ap­proval for a rare form of mesothe­lioma

7 months ago
R&D
Pharma

Sen­a­tors tell FDA that ‘greater ac­tion is need­ed’ to use man­u­fac­tur­ing tech in US sup­ply chains

7 months ago
Pharma
FDA+

Roivant makes an­oth­er deal, sell­ing Der­ma­vant to Organon for up to $1.2B

7 months ago
Deals

With few ef­fi­ca­cy de­tails, In­sil­i­co claims a Phase 2a win in lat­est AI read­out

8 months ago
R&D
AI

No­vo Nordisk signs ge­net­ic med­i­cine pact, ink­ing deal with NanoVa­tion

8 months ago
Deals

You bet your life: Af­ter I was di­ag­nosed with a rare can­cer, I dis­cov­ered how a small band of physi­cian-sci­en­tists ...

8 months ago
Bioregnum
R&D

Ex­clu­sive: For­mer Ama­zon Phar­ma­cy ex­ecs back Me­vo, a start­up bring­ing on­line pre­scrib­ing to Brazil

8 months ago
Financing
Health Tech

Ther­at­e­ch­nolo­gies' HIV drug to face sup­ply is­sues in 2025 over third-par­ty fa­cil­i­ty shut­down 

8 months ago
Pharma
FDA+

All of 23and­Me's in­de­pen­dent board mem­bers re­sign over dis­agree­ments with CEO

8 months ago
People
Health Tech

No­var­tis’ Kisqali snags FDA ap­proval to re­duce re­cur­rence in pa­tients with ear­ly forms of breast can­cer

8 months ago
Pharma
FDA+

Con­duct­ing tri­als via rou­tine clin­i­cal prac­tice: FDA ex­plains how in new draft guid­ance

8 months ago
R&D
FDA+

CD­MO Serán sets out to build first com­mer­cial fa­cil­i­ty, with a $200M in­vest­ment led by Bain Cap­i­tal

8 months ago
Pharma
Manufacturing

Co­herus warns of lim­it­ed can­cer drug sup­ply due to third-par­ty ‘ca­pac­i­ty con­straints’

8 months ago
Pharma
Manufacturing

Capri­cor ex­pands DMD pact with Nip­pon Shinyaku; Ab­b­Vie’s new eye deal

8 months ago
News Briefing

Cigna sues FTC, call­ing for with­draw­al of 'bi­ased, er­ro­neous' PBM re­port

8 months ago
Pharma
Law

Bad trip: How cul­ture con­flict and a need for cash near­ly broke Lykos

8 months ago
People
In Focus

Sun, sur­pris­es and new sum­mits at Eu­rope’s biggest can­cer con­fer­ence

8 months ago
R&D
Pharma

Af­ter land­ing a key win in a com­mon can­cer con­di­tion, Pfiz­er faces a big test in Phase 3

8 months ago
R&D
Pharma

Mer­ck and Dai­ichi’s re­ject­ed HER3 ADC clears a Phase 3 in cer­tain lung can­cers

8 months ago
R&D

Nu­ra Bio rais­es $68M for clin­i­cal tests of SARM1 in­hibitor to po­ten­tial­ly slow or pre­vent nerve de­gen­er­a­tion

8 months ago
Financing
R&D

Em­met Stephen­son gives $150M to City of Hope for pan­cre­at­ic can­cer, cre­at­ing mil­lion-dol­lar re­search prize

8 months ago
Financing
R&D

23andMe heads to ES­MO to tout its two clin­i­cal-stage drugs af­ter scrap­ping dis­cov­ery team

8 months ago
Startups
R&D
First page Previous page 949596979899100 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times